AnesthesiaNCT07352826
The Effect of Blood Carboxyhemoglobin Levels on NF-kB, NRF2 and PGC-1α During Low-flow and Normal-flow Anesthesia
A study testing low-flow anasthesia and Normal akımlı anestezi in people with Anesthesia, run by Ataturk Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that exerts diverse biological effects across tissues and organs. At high concentrations, it is recognized as toxic because of harmful effects such as tissue hypoxia, oxidative stress, peroxynitrite formation, inflammation, apoptosis, and immune damage. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Anesthesia
- What is being tested?
- low-flow anasthesia and Normal akımlı anestezi
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 20 Feb 2026to 31 Aug 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- aged 18-70 years
- classified as ASA I
- scheduled for inhalational anesthesia lasting ≥2 hours
Who cannot join
- Patients with cardiovascular disease, respiratory system disease, hepatic or renal disease
- pregnant or breastfeeding women
- trauma patients
- those undergoing emergency surgery
- procedures lasting <2 hours
- those receiving intraoperative blood transfusion
- smokers
- individuals who decline participation
Trial locations and contacts
1 site in 1 country.
About this study
Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that exerts diverse biological effects across tissues and organs. At high concentrations, it is recognized as toxic because of harmful effects such as tissue hypoxia, oxidative stress, peroxynitrite formation, inflammation, apoptosis, and immune damage. However, the endogenous production of CO suggests that it may confer protective mechanisms to the host. These protective effects include inhibition of platelet activation, smooth muscle relaxation, vasoactive properties, anti-inflammatory and anti-apoptotic actions, and beneficial influences on neurotransmission. Despite its toxic potential, low-concentration endogenous CO may provide protection linked to the body's defense mechanisms. In this study, we aimed to investigate the anti-apoptotic effects of carbon monoxide at low concentrations. To this end, the relationships between COHb levels and plasma levels of NF-κB, NRF2, and PGC-1α were analyzed statistically.
Read the detailed description
A total of 120 patients aged 18-70 years, classified as ASA I and scheduled for inhalational anesthesia lasting ≥2 hours, will be included. Patients with cardiovascular disease, respiratory system disease, hepatic or renal disease; pregnant or breastfeeding women; trauma patients; those undergoing emergency surgery; procedures lasting <2 hours; those receiving intraoperative blood transfusion; smokers; and individuals who decline participation will be excluded.
All participants who agree to join the study will read and sign an informed consent form describing the study. Preoperative evaluations will be performed 1 day before surgery. Thirty minutes before surgery, a 22G intravenous cannula will be inserted, and 8 mL of blood will be drawn into a yellow-cap gel biochemistry tube and 1.5 mL into a blood gas syringe containing 60 IU of dry heparin. Biochemistry samples will be centrifuged at 4000 rpm for 10 minutes in the medical biochemistry laboratory. The separated sera will be transferred to Eppendorf tubes and stored at -80 °C until the day of analysis. Blood gas samples will be analyzed on a blood gas analyzer (Radiometer ABL 520, Copenhagen, Denmark). After blood sampling, an infusion of 0.9% sodium chloride (NaCl) at 10 mL/kg/h will be initiated. Patients will receive IV premedication with 1.5 mg midazolam; on the operating table, ECG, noninvasive blood pressure, and peripheral oxygen saturation (SpO₂) will be monitored. Before induction, all patients will undergo preoxygenation with O₂ at 6 L/min via face mask for 3 minutes.
For induction of anesthesia, fentanyl 1 µg/kg (Fentanyl Citrate, Abbott Laboratories, North Chicago, USA) and propofol 2 mg/kg IV (Propofol, Fresenius Kabi, Sweden) will be administered over 20-30 seconds. After loss of the eyelash reflex, rocuronium bromide 0.6 mg/kg (Esmeron, Organon, Netherlands) will be given IV for neuromuscular blockade, and endotracheal intubation will be performed with a cuffed tube of appropriate size for the patient's age and body habitus. Following propofol administration and until intubation, all patients will be manually ventilated with 100% O₂. After intubation, mechanical ventilation will be provided with an anesthesia machine (Datex-Ohmeda Aisys CS2, Madison, USA) in volume-controlled mode with a tidal volume of 6-8 mL/kg, respiratory rate of 12-14/min, and PEEP of 5 cmH₂O. Soda lime will be used as the CO₂ absorbent (Sorbolime, Berkim, Türkiye), and replacement of the absorbent will be verified before induction for each patient.
Patients will be randomly assigned to one of two groups: Group LF (low-flow, n=60) and Group NF (normal-flow, n=60). In both groups, fresh gas flow (FGF) will be set at 4 L/min (O₂ 50%, air 50%) until the minimum alveolar concentration (MAC) reaches 1. In Group LF, FGF will then be maintained at 0.6 L/min (O₂ 50%, air 50%), with desflurane adjusted to maintain MAC = 1. In Group NF, FGF will be maintained at 2 L/min (O₂ 50%, air 50%), with desflurane adjusted to maintain MAC = 1. In both groups, blood sampling will be repeated at the 2nd hour of surgery.
During the final 30 minutes of surgery, patients will receive postoperative analgesia consisting of tramadol HCl (Contramal, Türkiye) 100 mg IV, paracetamol (Partemol, Türkiye) 1 g IV, and dexketoprofen (Ketavel, Türkiye) 50 mg IV. In the normal-flow group, after placement of the final skin suture, the inhalational agent will be discontinued and the carrier gas switched to 100% O₂; FGF will be increased to 8 L/min. In the low-flow group, the inhalational agent will be discontinued 20 minutes before the anticipated end of surgery; FGF will be maintained at 0.6 L/min until the final skin suture and then increased to 8 L/min. After the return of spontaneous breathing, neostigmine 0.03 mg/kg (Plantigmin, Türkiye) and atropine 0.01 mg/kg (Turktıpsan, Türkiye) will be administered in both groups to achieve extubation.
Postoperatively, patients will be transferred to the post-anesthesia care unit, where respiratory and hemodynamic parameters will be monitored for 30 minutes before transfer to the ward. In both groups, blood sampling will be repeated at postoperative hour 24 using the same method. The following variables will be recorded: duration of anesthesia, SpO₂, venous blood gas results, hemodynamic parameters, postoperative recovery time and quality, and postoperative complications (e.g., nausea and vomiting). Blood samples obtained in the preoperative, intraoperative, and postoperative periods will be centrifuged and stored at -80 °C. Following biochemical analysis, COHb, NF-κB, NRF2, and PGC-1α levels will be subjected to statistical analysis.
- Conditions
- Anesthesia
- Being tested
- low-flow anasthesia, Normal akımlı anestezi
- Keywords
- low flow anesthesia, COHb, NF-kB, NRF2, PGC-1 alpha
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
low-flow anasthesiaBehavioural
In Group LF, FGF will then be maintained at 0.6 L/min (O₂ 50%, air 50%), with desflurane adjusted to maintain MAC = 1
Normal akımlı anesteziBehavioural
In Group NF, FGF will be maintained at 2 L/min (O₂ 50%, air 50%) with desflurane adjusted to maintain MAC = 1..
| Study group | Role | What they receive |
|---|---|---|
| low-flow | Experimental | low flow Receives: Behavioral: low-flow anasthesia; Behavioral: Normal akımlı anestezi |
| normal flow | Experimental | normal flow Receives: Behavioral: low-flow anasthesia; Behavioral: Normal akımlı anestezi |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesia
COHb concentrations
Measured: 24 HOUR
Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesia
NF-kB concentrations
Measured: 24 HOUR
Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesi
NRF2 concentrations
Measured: 24 HOUR
Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesi
PGC-1α concentrations
Measured: 24 HOUR
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2026
- Study start20 Feb 2026
- Primary completion31 May 2026
- Study completion31 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AnesthesiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ataturk Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Veysel Koksal, MD, Ataturk Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07352826
- Sponsor's protocol ID
- B.30.2.YYU.0.01.00.00/91
- Status last verified
- Oct 2026
- First submitted
- 15 Sep 2025
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Blood Carboxyhemoglobin Levels on NF-kB, NRF2 and PGC-1α During Low-flow and Normal-flow Anesthesia
- ClinicalTrials.gov ID
- NCT07352826
- Acronym / sponsor ID
- B.30.2.YYU.0.01.00.00/91
- Conditions
- Anesthesia
- Keywords
- low flow anesthesia, COHb, NF-kB, NRF2, PGC-1 alpha
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- Ataturk Training and Research HospitalUniversity, hospital or other
- Study start
- 20 Feb 2026 (actual)
- Primary completion
- 31 May 2026 (actual)
- Study completion
- 31 Aug 2026 (actual)
- First posted
- 20 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Carbon monoxide (CO) is a colorless, odorless, and tasteless gas that exerts diverse biological effects across tissues and organs. At high concentrations, it is recognized as toxic because of harmful effects such as tissue hypoxia, oxidative stress, peroxynitrite formation, inflammation, apoptosis, and immune damage. However, the endogenous production of CO suggests that it may confer protective mechanisms to the host. These protective effects include inhibition of platelet activation, smooth muscle relaxation, vasoactive properties, anti-inflammatory and anti-apoptotic actions, and beneficial influences on neurotransmission. Despite its toxic potential, low-concentration endogenous CO may provide protection linked to the body's defense mechanisms. In this study, we aimed to investigate the anti-apoptotic effects of carbon monoxide at low concentrations. To this end, the relationships between COHb levels and plasma levels of NF-κB, NRF2, and PGC-1α were analyzed statistically.
Detailed description
A total of 120 patients aged 18-70 years, classified as ASA I and scheduled for inhalational anesthesia lasting ≥2 hours, will be included. Patients with cardiovascular disease, respiratory system disease, hepatic or renal disease; pregnant or breastfeeding women; trauma patients; those undergoing emergency surgery; procedures lasting <2 hours; those receiving intraoperative blood transfusion; smokers; and individuals who decline participation will be excluded.
All participants who agree to join the study will read and sign an informed consent form describing the study. Preoperative evaluations will be performed 1 day before surgery. Thirty minutes before surgery, a 22G intravenous cannula will be inserted, and 8 mL of blood will be drawn into a yellow-cap gel biochemistry tube and 1.5 mL into a blood gas syringe containing 60 IU of dry heparin. Biochemistry samples will be centrifuged at 4000 rpm for 10 minutes in the medical biochemistry laboratory. The separated sera will be transferred to Eppendorf tubes and stored at -80 °C until the day of analysis. Blood gas samples will be analyzed on a blood gas analyzer (Radiometer ABL 520, Copenhagen, Denmark). After blood sampling, an infusion of 0.9% sodium chloride (NaCl) at 10 mL/kg/h will be initiated. Patients will receive IV premedication with 1.5 mg midazolam; on the operating table, ECG, noninvasive blood pressure, and peripheral oxygen saturation (SpO₂) will be monitored. Before induction, all patients will undergo preoxygenation with O₂ at 6 L/min via face mask for 3 minutes.
For induction of anesthesia, fentanyl 1 µg/kg (Fentanyl Citrate, Abbott Laboratories, North Chicago, USA) and propofol 2 mg/kg IV (Propofol, Fresenius Kabi, Sweden) will be administered over 20-30 seconds. After loss of the eyelash reflex, rocuronium bromide 0.6 mg/kg (Esmeron, Organon, Netherlands) will be given IV for neuromuscular blockade, and endotracheal intubation will be performed with a cuffed tube of appropriate size for the patient's age and body habitus. Following propofol administration and until intubation, all patients will be manually ventilated with 100% O₂. After intubation, mechanical ventilation will be provided with an anesthesia machine (Datex-Ohmeda Aisys CS2, Madison, USA) in volume-controlled mode with a tidal volume of 6-8 mL/kg, respiratory rate of 12-14/min, and PEEP of 5 cmH₂O. Soda lime will be used as the CO₂ absorbent (Sorbolime, Berkim, Türkiye), and replacement of the absorbent will be verified before induction for each patient.
Patients will be randomly assigned to one of two groups: Group LF (low-flow, n=60) and Group NF (normal-flow, n=60). In both groups, fresh gas flow (FGF) will be set at 4 L/min (O₂ 50%, air 50%) until the minimum alveolar concentration (MAC) reaches 1. In Group LF, FGF will then be maintained at 0.6 L/min (O₂ 50%, air 50%), with desflurane adjusted to maintain MAC = 1. In Group NF, FGF will be maintained at 2 L/min (O₂ 50%, air 50%), with desflurane adjusted to maintain MAC = 1. In both groups, blood sampling will be repeated at the 2nd hour of surgery.
During the final 30 minutes of surgery, patients will receive postoperative analgesia consisting of tramadol HCl (Contramal, Türkiye) 100 mg IV, paracetamol (Partemol, Türkiye) 1 g IV, and dexketoprofen (Ketavel, Türkiye) 50 mg IV. In the normal-flow group, after placement of the final skin suture, the inhalational agent will be discontinued and the carrier gas switched to 100% O₂; FGF will be increased to 8 L/min. In the low-flow group, the inhalational agent will be discontinued 20 minutes before the anticipated end of surgery; FGF will be maintained at 0.6 L/min until the final skin suture and then increased to 8 L/min. After the return of spontaneous breathing, neostigmine 0.03 mg/kg (Plantigmin, Türkiye) and atropine 0.01 mg/kg (Turktıpsan, Türkiye) will be administered in both groups to achieve extubation.
Postoperatively, patients will be transferred to the post-anesthesia care unit, where respiratory and hemodynamic parameters will be monitored for 30 minutes before transfer to the ward. In both groups, blood sampling will be repeated at postoperative hour 24 using the same method. The following variables will be recorded: duration of anesthesia, SpO₂, venous blood gas results, hemodynamic parameters, postoperative recovery time and quality, and postoperative complications (e.g., nausea and vomiting). Blood samples obtained in the preoperative, intraoperative, and postoperative periods will be centrifuged and stored at -80 °C. Following biochemical analysis, COHb, NF-κB, NRF2, and PGC-1α levels will be subjected to statistical analysis.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| low-flow | Experimental | Behavioral: low-flow anasthesia, Behavioral: Normal akımlı anestezilow flow |
| normal flow | Experimental | Behavioral: low-flow anasthesia, Behavioral: Normal akımlı anestezinormal flow |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- aged 18-70 years
- classified as ASA I
- scheduled for inhalational anesthesia lasting ≥2 hours
Key exclusion criteria (8 listed)
- Patients with cardiovascular disease, respiratory system disease, hepatic or renal disease
- pregnant or breastfeeding women
- trauma patients
- those undergoing emergency surgery
- procedures lasting <2 hours
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| low-flow anasthesiaIn Group LF, FGF will then be maintained at 0.6 L/min (O₂ 50%, air 50%), with desflurane adjusted to maintain MAC = 1 | Behavioural | low-flow, normal flow |
| Normal akımlı anesteziIn Group NF, FGF will be maintained at 2 L/min (O₂ 50%, air 50%) with desflurane adjusted to maintain MAC = 1.. | Behavioural | low-flow, normal flow |
Primary outcome
Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesia
Time frame: 24 HOUR
COHb concentrations
Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesia
Time frame: 24 HOUR
NF-kB concentrations
Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesi
Time frame: 24 HOUR
NRF2 concentrations
Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesi
Time frame: 24 HOUR
PGC-1α concentrations
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
Related trials for Anesthesia
Not yet recruitingObservational study
"Comparison of Oxygen Reserve Index (ORI), End-Tidal Oxygen, and Time-Based Preoxygenation Targets With Arterial Blood Gas During Preoxygenation
Preoxygenation Adequacy Assessed by Oxygen Reserve Index, End-tidal Oxygen and Arterial Blood Gas
RecruitingObservational study
Comparison of Hemodynamic Responses During Anesthesia Induction Using Eleveld and Schnider
Spinal (Fusion) Surgery, Total Intravenous Anesthesia
Not yet recruiting
A Randomized Controlled SaCo-VLM Trial
General Anaesthesia Using Supraglotic Airway
Not yet recruiting
Bispectral Index-Guided Propofol Sedation During Endoscopic Retrograde Cholangiopancreatography
Deep Sedation, Endoscopic Retrograde Cholangiopancreatography
RecruitingPhase 4
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing low-flow anasthesia and Normal akımlı anestezi in people with Anesthesia, run by Ataturk Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood COHb, NF-kB, NRF2, and PGC-1α levels during Low-Flow and Normal-Flow Anesthesia (time frame: 24 HOUR). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.